Related Experiment Videos
Complement C3-Targeted Therapy: Replacing Long-Held Assertions with Evidence-Based Discovery
Dimitrios C Mastellos1, Edimara S Reis2, Daniel Ricklin3
1Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Division of Biodiagnostic Sciences and Technologies, Institute of Nuclear and Radiological Sciences and Technology, Energy, and Safety (INRASTES), National Center for Scientific Research 'Demokritos', Aghia Paraskevi Attikis, 15310 Athens, Greece.
Abstract:
Complement dysregulation underlies several inflammatory disorders, and terminal complement inhibition has thus far afforded significant clinical gains. Nonetheless, emerging pathologies, fueled by complement imbalance and therapy-skewing genetic variance, underscore the need for more comprehensive, disease-tailored interventions. Modulation at the level of C3, a multifaceted orchestrator of the complement cascade, opens up prospects for broader therapeutic efficacy by targeting multiple pathogenic pathways modulated by C3-triggered proinflammatory crosstalk. Notably, C3 intervention is emerging as a viable therapeutic strategy for renal disorders with predominantly complement-driven etiology, such as C3 glomerulopathy (C3G). Using C3G as a paradigm, we argue that concerns about the feasibility of long-term C3 intervention need to be placed into perspective and weighed against actual therapeutic outcomes in prospective clinical trials.
Insights
Targeting complement component 3 (C3) offers a promising therapeutic strategy for inflammatory diseases like C3 glomerulopathy (C3G). This approach addresses complement imbalance and may provide broader efficacy than current treatments.
Area of Science:
- Immunology
- Nephrology
- Molecular Medicine
Background:
- Complement dysregulation is implicated in numerous inflammatory disorders.
- Terminal complement inhibition has shown clinical benefits but is insufficient for emerging pathologies.
- Genetic variations can influence complement pathways and treatment responses.
Purpose of the Study:
- To explore the therapeutic potential of modulating complement component 3 (C3) for inflammatory diseases.
- To highlight C3 intervention as a strategy for complement-driven renal disorders, using C3 glomerulopathy (C3G) as a model.
- To contextualize concerns regarding long-term C3 inhibition against potential clinical benefits.
Main Methods:
- Review of current literature on complement dysregulation and therapeutic interventions.
- Analysis of C3's role as a central mediator in the complement cascade.
- Examination of C3 glomerulopathy (C3G) as a case study for C3-targeted therapy.
Main Results:
- C3 acts as a key orchestrator, linking multiple inflammatory pathways.
- Targeting C3 offers potential for broader therapeutic efficacy compared to terminal complement inhibition.
- C3 intervention is a developing strategy for complement-mediated kidney diseases like C3G.
Conclusions:
- Modulating C3 presents a versatile approach to managing complement-driven inflammatory conditions.
- Further clinical trials are necessary to evaluate the long-term feasibility and outcomes of C3 inhibition.
- C3-targeted therapies hold promise for addressing unmet needs in inflammatory and renal disorders.